The US Food and Drug Administration (FDA) on Friday approved a migraine nasal spray made by Pfizer Inc, which could give patients an option for a fast-acting migraine relief.
Pfizer said, according to Reuters, that zavzprit, also known as zavigepant, is approved for use in acute migraine with and without aura, a word meaning any neurological disorder that occurs shortly before the onset of a migraine or during its progression.
The company told Reuters that the spray, whose price will be announced when it is launched in July, "It is expected to be comparable in price to other FDA-approved migraine medications" They belong to the same class of drugs.
Pfizer has added Zavesprit and other migraine drugs, including Nortec ODT, to its portfolio with the $11.6 billion acquisition of Biohaven Pharmaceuticals.
The drug contains a warning label advising patients to stop taking it if it causes a hypersensitivity reaction such as facial swelling or rash.
